MedTrace Logo

Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers

NCT04446065 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 524

Last updated 2020-09-09

No results posted yet for this study

Summary

The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure chemoprophylaxis to SARS-CoV-2.

Conditions

Interventions

DRUG

Previfenon®

Every capsule of Previfenon® (patent pending) provides 250 mg EGCG ≥ 98% purity with a carefully selected set of excipients to improve flowability, stabilize EGCG against early auto-oxidation, and increase its hepatoprotective activity with prolonged use.

DRUG

Placebo

Participants will receive placebo starch capsules (250 mg plus excipients) identical in appearance and taste to Previfenon® capsules in a double-blind manner.

Sponsors & Collaborators

  • Universidad Austral

    collaborator UNKNOWN

  • MELISA Institute Genomics & Proteomics Research SpA

    lead INDUSTRY

Principal Investigators

  • Elard S Koch, PhD · MELISA Institute Genomics & Proteomics Research SpA

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-09-30
Completion
2021-10-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04446065 on ClinicalTrials.gov